17:15 EDT Zevra Therapeutics files $350M mixed securities shelf
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics Unveils Promising KP1077 Phase 2 Results
- Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
- Zevra Therapeutics announces final results from Phase 2 trial of KP1077
- Zevra Therapeutics sees cash, equivalents extending cash runway into 2026
- Zevra Therapeutics reports Q1 EPS (40c), consensus (48c)